Contrasting ProSomnus (OSA) and The Competition

ProSomnus (NASDAQ:OSA) is one of 231 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare ProSomnus to related companies based on the strength of its valuation, institutional ownership, risk, analyst recommendations, profitability, earnings and dividends.

Insider & Institutional Ownership

70.0% of ProSomnus shares are held by institutional investors. Comparatively, 48.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 7.7% of ProSomnus shares are held by company insiders. Comparatively, 15.2% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for ProSomnus and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProSomnus	0	1	2	0	2.67
ProSomnus Competitors	1603	4332	8506	223	2.50

ProSomnus currently has a consensus target price of $2.33, suggesting a potential upside of 2,021.21%. As a group, “Surgical & medical instruments” companies have a potential upside of 24.94%. Given ProSomnus’ stronger consensus rating and higher possible upside, equities research analysts clearly believe ProSomnus is more favorable than its competitors.

Profitability

This table compares ProSomnus and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProSomnus	-87.14%	N/A	-106.30%
ProSomnus Competitors	-737.51%	-146.94%	-29.30%

Valuation & Earnings

This table compares ProSomnus and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ProSomnus	$27.65 million	-$24.09 million	-0.07
ProSomnus Competitors	$1.06 billion	$4.24 million	1.62

ProSomnus’ competitors have higher revenue and earnings than ProSomnus. ProSomnus is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

ProSomnus has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, ProSomnus’ competitors have a beta of 0.61, suggesting that their average stock price is 39% less volatile than the S&P 500.

Summary

ProSomnus competitors beat ProSomnus on 7 of the 13 factors compared.

About ProSomnus

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.